Walmsley: GSK Will Take Incremental Deal-Making Approach In Building Up Oncology

25 Sep 2019

GSK has more than doubled its oncology pipeline since July 2018, and the company's CEO thinks smaller deals and a new site combining R&D and manufacturing will enable its progress to continue.

GSK CEO Emma Walmsley addresses reporters at new GSK plant — GSK CEO Emma Walmsley at the company's new US manufacturing facility • Source: Joseph Haas

GlaxoSmithKline PLC's $5.1bn acquisition of Tesaro Inc. sped up the company's revamp of its cancer R&D engine, but deals of that size will be outliers for now, CEO Emma Walmsley indicated on 25 September.

Speaking at the opening of a $120m biologics manufacturing and R&D facility outside Philadelphia, the exec said GSK needs to...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

Start your 7-day free trial
Explore trusted news, analysis, and insights
Access comprehensive global coverage
Enjoy instant access – no credit card required

Start Free Trial

Already a subscriber?

Will AstraZeneca Reach Summit And Be A PD-1xVEGF Player?

04 Jul 2025

• By Kevin Grogan

Rumor mill suggests a $15bn licensing deal for ivonescimab is in the offing.

In Brief: BioVersys And Shionogi Align In Non-Tuberculous Mycobacteria R&D

02 Jul 2025

• By Joseph Haas

Deal Snapshot: Having recently raised an $89m IPO, BioVersys is partnering on and optioning rights to a preclinical NTM development program with Shionogi.

BerGenBio Plumps For Oncoinvent From Long List Of 50 Suitors

02 Jul 2025

• By Kevin Grogan

The merger with a fellow Norwegian biotech comes a few months after its lead asset, bemcentinib, bit the dust.

BlissBio Goes Solo On HER2-Targeting ADC After Eisai Exit

02 Jul 2025

• By Dexter Jie Yan

BlissBio is to single-handedly move BB-1701, its eribulin-containing, HER2-targeting antibody-drug conjugate, into a global pivotal Phase II/III program for HER2-expressing, Enhertu-resistant breast cancer.